The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis

Journal of Rheumatology

Volumn 32, Issue SUPPL. 72, 2005, Pages 46-47

  Haraoui, Boulos ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Anti tumor Necrosis Factor Therapy; Biologic Therapy; Disease Modifying Antiinflammatory Drugs; Rheumatoid Arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTHROPATHY; CONFERENCE PAPER; DISEASE DURATION; HUMAN; MONOTHERAPY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RADIOGRAPHY; RHEUMATOID ARTHRITIS; SYNOVITIS; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; METHODOLOGY; REVIEW; RHEUMATOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; RHEUMATOLOGY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17144369166     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
2. Klareskog L, van der Heijde DM, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
3. Smolen JS, Emery P, Bathon J, et al. Treatment of early RA with infliximab plus MTX or MTX alone: preliminary results of ASPIRE trial [abstract]. Ann Rheum Dis 2003; 63 Suppl1: 0P0001.
4. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
5. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
6. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
7. Keystone E, Kavanaugh A, Sharp J, et al. Adalimumab (D2E7), a fully human anti-TNF alpha monoclonal antibody inhibits the progression of structure joint damage in patients with active RA despite concomitant methotrexate therapy [abstract]. Arthritis Rheum 2002;46 Suppl:S205.